CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

2: Standard of careWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug18 1: Naproxen Wiki 1.00

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D016638 Critical Illness NIH 0.14

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection

The symptoms of respiratory distress caused by COVID-19 may be reduced by drugs combining anti-inflammatory and antiviral effects. This dual effect may simultaneously protect severely-ill patients and reduce the viral load, therefore limiting virus dissemination We want to demonstrate the superiority of naproxen (anti-inflamatory drug) treatment addition to standard of care compared to standard of care in term of 30-day mortality.

NCT04325633 COVID-19 Drug: 1: Naproxen Drug: 2: Standard of care
MeSH:Critical Illness

Primary Outcomes

Measure: Mortality all causes at day30

Time: at day30

Secondary Outcomes

Measure: Number of days alive free of mechanical ventilation

Time: during 30 days after randomization

Measure: Number of days alive outside

Time: during 30 days after randomization

Measure: Number of days alive outside hospital

Time: during 30 days after randomization

Measure: Maximal changes in Sofa score

Time: in the first 7 days after randomization

Measure: Time to negativation of virus titer in the nasopharyngeal aspirate (NPA)

Time: during 90 days after randomization

No related HPO nodes (Using clinical trials)